AR026819A1 - Dispositivo osmotico que contiene venlafaxina y un agente antipsicotico - Google Patents

Dispositivo osmotico que contiene venlafaxina y un agente antipsicotico

Info

Publication number
AR026819A1
AR026819A1 ARP010100086A ARP010100086A AR026819A1 AR 026819 A1 AR026819 A1 AR 026819A1 AR P010100086 A ARP010100086 A AR P010100086A AR P010100086 A ARP010100086 A AR P010100086A AR 026819 A1 AR026819 A1 AR 026819A1
Authority
AR
Argentina
Prior art keywords
osmotic
external cover
antipsychotic agent
osmotic device
device containing
Prior art date
Application number
ARP010100086A
Other languages
English (en)
Original Assignee
Osmotica Argentina S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osmotica Argentina S A filed Critical Osmotica Argentina S A
Publication of AR026819A1 publication Critical patent/AR026819A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion provee un dispositivo osmotico que contiene venlafaxina de liberacion controlada en el nucleo en combinacion con un agenteantipsicotico en una cubierta externa de liberacion rápida. Un amplio rango de agentes antipsicoticos pued en ser utilizados en este dispositivo. Realizacionesparticulares de la invencion proveen dispositivos osmoticos con perfiles de liberacion predeterminados. Una realizacion del dispositivo osmotico incluye unacubierta externa que ha sido aplicada por pulverizacion en lugar de ser aplicada por compresion sobre el dispositivo. El dispositivo con la cubierta externaaplicada por pulverizacion es más pequeno y fácil de tragar que un dispositivo similar con una cubierta externa aplicada por compresion . El dispositivo es utilpara el tratamiento de los desordenes relacionados con la depresion, la ansiedad o la psicosis.
ARP010100086A 2000-01-13 2001-01-09 Dispositivo osmotico que contiene venlafaxina y un agente antipsicotico AR026819A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17582200P 2000-01-13 2000-01-13
US09/728,276 US6572890B2 (en) 2000-01-13 2000-11-30 Osmotic device containing venlafaxine and an anti-psychotic agent

Publications (1)

Publication Number Publication Date
AR026819A1 true AR026819A1 (es) 2003-02-26

Family

ID=26871608

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100086A AR026819A1 (es) 2000-01-13 2001-01-09 Dispositivo osmotico que contiene venlafaxina y un agente antipsicotico

Country Status (8)

Country Link
US (2) US6572890B2 (es)
EP (1) EP1246614B1 (es)
AR (1) AR026819A1 (es)
AT (1) ATE553752T1 (es)
AU (1) AU2001227731A1 (es)
CA (1) CA2396156C (es)
ES (1) ES2386804T3 (es)
WO (1) WO2001051041A1 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
CA2428817C (en) * 2000-11-17 2010-06-01 Takeda Chemical Industries, Ltd. Copolyvidone-containing preparation
US20050244498A1 (en) * 2001-09-14 2005-11-03 Biovail Laboratories, Inc. Modified-release compositions of at least one form of venlafaxine
US20050208132A1 (en) * 2002-07-29 2005-09-22 Gayatri Sathyan Methods and dosage forms for reducing side effects of benzisozazole derivatives
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
MXPA05000294A (es) 2002-07-30 2005-08-19 Peter Migaly Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.
CA2503380A1 (en) * 2002-10-25 2004-05-06 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions containing venlafaxine
WO2004047718A2 (en) * 2002-11-28 2004-06-10 Themis Laboratories Private Limited Process for manufacturing sustained release microbeads containing venlafaxine hci
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US8293799B2 (en) * 2003-12-29 2012-10-23 Osmotica Keresleedelmo és Szolgáltató KFT Osmotic device containing a venlafaxine salt and a salt having an ion in common
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
AR042550A1 (es) * 2002-12-23 2005-06-22 Osmotica Argentina S A Una forma de dosificacion farmaceutica que comprende venlafaxina y memantina
CN1989968B (zh) 2002-12-27 2011-05-11 大塚制药株式会社 用于治疗情绪障碍的喹诺酮衍生物和5-羟色胺再摄取抑制剂
AR042806A1 (es) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
WO2004089334A2 (en) * 2003-03-31 2004-10-21 Alza Corporation Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems
CA2520775A1 (en) 2003-03-31 2004-10-21 Alza Corporation Non-aqueous single phase vehicles and formulations utilizing such vehicles
KR20060017749A (ko) 2003-03-31 2006-02-27 알자 코포레이션 내압 소멸 수단을 갖는 삼투성 펌프
JP2007502856A (ja) * 2003-05-16 2007-02-15 ファイザー・プロダクツ・インク 精神病性障害および抑うつ性障害の治療
WO2004100955A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Anxiety treatments with ziprasidone
IN2003MU00504A (es) * 2003-06-05 2005-05-13 Alembic Ltd
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
AU2004269858A1 (en) * 2003-09-04 2005-03-17 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and Loxapine
US7611728B2 (en) * 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
US20050142203A1 (en) * 2003-12-30 2005-06-30 Grant Heinicke Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
US8574626B2 (en) 2004-12-03 2013-11-05 Osmotica Kereskedelmi és Szolgáltató KFT Osmotic device containing amantadine and an osmotic salt
US8252331B2 (en) * 2004-12-03 2012-08-28 Osmotica Kereskedelmi és Szolgáltató, KFT Osmotic device containing amantadine and an osmotic salt
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
EA200701591A1 (ru) * 2005-01-26 2008-02-28 Элан Фарма Интернэшнл Лимитед Композиции с контролируемым высвобождением, содержащие антипсихотическое средство
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
WO2007073702A2 (es) * 2005-12-29 2007-07-05 Osmotica Corp. Comprimido multicapa con combinación de triple liberación
KR100774613B1 (ko) * 2006-05-26 2007-11-12 한국화학연구원 수불용성 고분자로 이루어진 서방형 약물 전달체
CA2651855C (en) 2006-05-30 2011-08-02 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
TW200815045A (en) * 2006-06-29 2008-04-01 Jazz Pharmaceuticals Inc Pharmaceutical compositions of ropinirole and methods of use thereof
ES2422864T3 (es) 2006-08-09 2013-09-16 Intarcia Therapeutics, Inc Sistemas de liberación osmótica y unidades de pistón
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
US20080152870A1 (en) * 2006-12-22 2008-06-26 Katsunori Takada Transparent electrically-conductive hard-coated substrate and method for producing the same
PT2157967E (pt) 2007-04-23 2013-04-03 Intarcia Therapeutics Inc Formulações de suspensões de péptidos insulinotrópicos e suas utilizações
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
US20100209489A1 (en) * 2009-02-04 2010-08-19 Supernus Pharmaceuticals, Inc. Formulations of desvenlafaxine
KR101823699B1 (ko) 2009-09-28 2018-01-30 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
WO2011091418A1 (en) * 2010-01-25 2011-07-28 Northeastern University Screening method for adverse side effects of a therapeutic pharmaceutical drug
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly
BR112022013784A2 (pt) 2020-01-13 2022-10-11 Durect Corp Sistemas de distribuição de fármacos de liberação prolongada com impurezas reduzidas e métodos relacionados

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
DE69435095T2 (de) * 1993-06-28 2009-07-02 Wyeth Neue Behandlungsmethoden durch Verwendung von Phenethylaminderivaten
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
US5530013A (en) * 1994-02-14 1996-06-25 American Home Products Corporation Venlafaxine in the inducement of cognition enhancement
US5506270A (en) * 1995-01-30 1996-04-09 American Home Products Corporation Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
AU7706598A (en) * 1997-05-30 1998-12-30 Laboratorios Phoenix U.S.A., Inc. Multi-layered osmotic device
ZA985765B (en) * 1997-07-02 1999-08-04 Merck & Co Inc Polymorphic form of a tachykinin receptor antagonist.
US6060642A (en) * 1997-08-15 2000-05-09 The Regents Of The University Of California Serotonin 5-HT6 receptor knockout mouse
US6352721B1 (en) * 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
JP3965956B2 (ja) * 2001-09-28 2007-08-29 国産電機株式会社 電子式燃料噴射制御装置

Also Published As

Publication number Publication date
AU2001227731A1 (en) 2001-07-24
EP1246614A1 (en) 2002-10-09
US20030219483A1 (en) 2003-11-27
EP1246614B1 (en) 2012-04-18
CA2396156C (en) 2008-08-12
US7008641B2 (en) 2006-03-07
ES2386804T3 (es) 2012-08-31
US20010048943A1 (en) 2001-12-06
WO2001051041A1 (en) 2001-07-19
EP1246614A4 (en) 2004-04-21
ATE553752T1 (de) 2012-05-15
CA2396156A1 (en) 2001-07-19
US6572890B2 (en) 2003-06-03

Similar Documents

Publication Publication Date Title
AR026819A1 (es) Dispositivo osmotico que contiene venlafaxina y un agente antipsicotico
UY26534A1 (es) Dispositivo osmótico que contiene alprazolam y un agente antipsicótico
AR026818A1 (es) Dispositivo osmotico que contien pseudoefedrina y un antagonista h1
DOU2000000116U (es) Paño limpiador que contiene un agente antimicrobiano que se libera de manera controlada
GT200400085A (es) Peliculas consumibles oralmente de disolucion rapida que contienen un almidon modificado para la mejora de laresistenciaal calor y a la humedad.
GT200200105A (es) Nueva composicion farmaceutica
CR9609A (es) Formulaciones de una sal de bupropion de liberacion modificada
CL2018001420A1 (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853)
ES2161473T3 (es) Metodo y composicion para rehumedecer lentes de contacto y aliviar la sequedad ocular.
CU23262A3 (es) Jeringa de seguridad con aguja retraible de intercambio
ATE369125T1 (de) Bioadhäsiver schaumstoffilm mit hinhaltender wirkstoffreigabe
AR024159A1 (es) Nuevo uso de compuestos como agentes antibacterianos
AR034660A1 (es) Nebulizador para la aplicacion de liquidos sobre la cornea del ojo
BRPI0316616B8 (pt) emplastro térmico com efeito térmico suficiente que torna a sensação agradável mais duradoura e irritação residual mais reduzida
AR034200A1 (es) Agente para el cuidado de lentes de contacto, su uso, y procedimiento de limpieza
BR0105730A (pt) Tampão contra pó ajustável
AR034712A1 (es) Forma de dosificacion de nucleo suave, de revestimiento fragil
SV1998000131A (es) Formulaciones de accion prolongada ref. ahp-95011-1-c1
AR012193A1 (es) Nuevas combinaciones terapeuticas
CR10289A (es) "estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva"(divisional)
SE9904681D0 (sv) Magnetkopplingsanordning på ett leksaksfordon
AR036085A1 (es) Formas de dosificacion y procedimiento para su fabricacion
ES2184880T3 (es) Asociacion hormonal estrogeno-progestageno, su procedimiento de preparacion y su utilizacion en medicamentos.
ES2180729T3 (es) Tratamiento terapeutico combinado de las patologias hiperproliferantes.
UY26535A1 (es) Dispositivo osmótico que contiene venlafaxina y un agente antipsicóptico

Legal Events

Date Code Title Description
FC Refusal